Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years
第3相
完了
NCT00761631
| 対象疾患 | Healthy Subjects |
|---|
| 相 | 第3相 |
|---|
| スポンサー | Pfizer |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 1,200 名 |
|---|
| 介入（薬剤） | 13 valent pneumococcal conjugate vaccine |
|---|
| 開始日 | 2008年11月18日 |
|---|
| 完了日 | 2010年8月10日 |
|---|
| 結果公開日 | 2011年8月10日 |
|---|
概要
This open-label, multicenter study is designed to evaluate the safety, tolerability and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy children aged more than 15 months up to less than 18 years.
Percentage of Participants Achieving Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to (≥) 0.35 Micrograms Per Milliliter (mcg/mL) Measured 1 Month After Vaccination in Group 1 and 2
28 to 42 days after dose 2 for Group 1 and 28 to 42 days after dose 1 for Group 2 · Percentage of participants
| 13vPnC Group 1 (Cohort 1) | 98.2 Percentage of participants |
|---|
| 13vPnC Group 2 (Cohort 1) | 100.0 Percentage of participants |
|---|
| 13vPnC Group 1 (Cohort 1) | 100.0 Percentage of participants |
|---|
| 13vPnC Group 2 (Cohort 1) | 100.0 Percentage of participants |
|---|
| 13vPnC Group 1 (Cohort 1) | 100.0 Percentage of participants |
|---|
| 13vPnC Group 2 (Cohort 1) | 100.0 Percentage of participants |
|---|
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Measured 1 Month After Vaccination in Group 3
28 to 42 days after dose 1 for Group 3 · mcg/mL
| 13vPnC Group 3 | 8.45 mcg/mL |
|---|
| 13vPnC Group 3 | 53.56 mcg/mL |
|---|
| 13vPnC Group 3 | 9.51 mcg/mL |
|---|
| 13vPnC Group 3 | 29.36 mcg/mL |
|---|
| 13vPnC Group 3 | 8.23 mcg/mL |
|---|
| 13vPnC Group 3 | 17.58 mcg/mL |
|---|
Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination in Group 3 and 4
28 to 42 days after dose 1 for Group 3 and 4 · titer
| 13vPnC Group 3 | 6912 titer |
|---|
| 13vPnC Group 4 | 4629 titer |
|---|
| 13vPnC Group 3 | 14224 titer |
|---|
| 13vPnC Group 4 | 14996 titer |
|---|
| 13vPnC Group 3 | 4485 titer |
|---|
| 13vPnC Group 4 | 4733 titer |
|---|
| GMT Ratio | 1.5 (95% CI 1.24–1.80) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。